☰

Razelle Kurzrock - Publications

Affiliations: 
The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Molecular Biology, Cell Biology, Genetics, Oncology
Tree Info Grants Similar researchers PubMed Report error

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Louie BH, Kato S, Kim KH, Lim HJ, Okamura R, Eskander RN, Botta G, Patel H, Lee S, Lippman SM, Sicklick JK, Kurzrock R. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. Npj Precision Oncology. 6: 67. PMID 36138116 DOI: 10.1038/s41698-022-00309-0  0.304
2020 Tsimberidou AM, Fountzilas E, Bleris L, Kurzrock R. Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in Cancer Biology. PMID 32950605 DOI: 10.1016/J.Semcancer.2020.09.007  0.319
2020 Bohan SS, Sicklick JK, Kato SM, Okamura R, Miller VA, Leyland-Jones B, Lippman SM, Kurzrock R. Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. The Oncologist. PMID 32949172 DOI: 10.1002/Onco.13532  0.37
2020 Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 9: 1781997. PMID 32923144 DOI: 10.1080/2162402X.2020.1781997  0.344
2020 Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, ... ... Kurzrock R, et al. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology. 9: 1773200. PMID 32923131 DOI: 10.1080/2162402X.2020.1773200  0.303
2020 Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Molecular Oncology. PMID 32881280 DOI: 10.1002/1878-0261.12791  0.388
2020 Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treatment Reviews. 90: 102091. PMID 32877777 DOI: 10.1016/J.Ctrv.2020.102091  0.384
2020 Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Frontiers in Oncology. 10: 1312. PMID 32850413 DOI: 10.3389/Fonc.2020.01312  0.345
2020 Kurzrock R. Selpercatinib Aimed at -Altered Cancers. The New England Journal of Medicine. 383: 868-869. PMID 32846067 DOI: 10.1056/Nejme2024831  0.34
2020 Agashe R, Kurzrock R. Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers. 12. PMID 32825548 DOI: 10.3390/Cancers12092361  0.379
2020 Subbiah V, Solit DB, Chan TA, Kurzrock R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32771306 DOI: 10.1016/J.Annonc.2020.07.002  0.312
2020 Baumgartner JM, Riviere P, Lanman RB, Kelly KJ, Veerapong J, Lowy AM, Kurzrock R. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Annals of Surgical Oncology. 27: 3259-3267. PMID 32767050 DOI: 10.1245/S10434-020-08331-X  0.344
2020 Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Marebiona M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Molecular Cancer Therapeutics. PMID 32747422 DOI: 10.1158/1535-7163.Mct-20-0161  0.348
2020 Schperberg AV, Boichard A, Tsigelny IF, Richard SB, Kurzrock R. Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. International Journal of Cancer. PMID 32745254 DOI: 10.1002/Ijc.33240  0.326
2020 Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. Comprehensive Genomic Landscape and Precision Therapeutic Approach in Biliary Tract Cancers. International Journal of Cancer. PMID 32700810 DOI: 10.1002/Ijc.33230  0.331
2020 Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, et al. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers. 12. PMID 32630797 DOI: 10.3390/Cancers12071768  0.307
2020 Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. Role of ultra-violet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Molecular Oncology. PMID 32530570 DOI: 10.1002/1878-0261.12748  0.347
2020 Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. Transcriptomic silencing as a potential mechanism of treatment resistance. Jci Insight. 5. PMID 32493840 DOI: 10.1172/Jci.Insight.134824  0.331
2020 Li AM, Boichard A, Felip E, Kurzrock R. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Critical Reviews in Oncology/Hematology. 151: 102990. PMID 32485428 DOI: 10.1016/J.Critrevonc.2020.102990  0.303
2020 Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Medicine. 12: 45. PMID 32430031 DOI: 10.1186/S13073-020-00743-4  0.318
2020 Sicklick JK, Kato S, Okamura R, Kurzrock R. Precision oncology: the intention-to-treat analysis fallacy. European Journal of Cancer (Oxford, England : 1990). 133: 25-28. PMID 32422506 DOI: 10.1016/J.Ejca.2020.04.002  0.356
2020 Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology & Oncology. 9: 7. PMID 32337094 DOI: 10.1186/S40164-020-00159-1  0.348
2020 Baumgartner JM, Riviere P, Kurzrock R. ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Annals of Surgical Oncology. PMID 32303875 DOI: 10.1245/S10434-020-08466-X  0.307
2020 Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews. 86: 102019. PMID 32251926 DOI: 10.1016/J.Ctrv.2020.102019  0.387
2020 Bieg-Bourne CC, Okamura R, Kurzrock R. Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. Molecular Oncology. PMID 32187847 DOI: 10.1002/1878-0261.12672  0.315
2020 Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 9: 1708065. PMID 32117584 DOI: 10.1080/2162402X.2019.1708065  0.308
2020 Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. Journal For Immunotherapy of Cancer. 8. PMID 32111729 DOI: 10.1136/Jitc-2019-000438  0.307
2020 Cohen PR, Kurzrock R. Basal Cell Carcinoma: Management of Advanced or Metastatic Cancer with Checkpoint Inhibitors and Concurrent Paradoxical Development of New Superficial Tumors. Journal of the American Academy of Dermatology. PMID 32109540 DOI: 10.1016/J.Jaad.2020.02.052  0.334
2020 Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 412-421. PMID 32067683 DOI: 10.1016/J.Annonc.2019.11.018  0.366
2020 Adashek JJ, Kato S, Lippman SM, Kurzrock R. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Medicine. 12: 16. PMID 32066498 DOI: 10.1186/S13073-020-0714-Y  0.372
2020 Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. PMID 32062691 DOI: 10.1007/S00280-020-04038-8  0.369
2020 Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? The Oncologist. 25: 94-98. PMID 32043794 DOI: 10.1634/Theoncologist.2019-0636  0.394
2020 Saunders IM, Goodman AM, Kurzrock R. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. The Oncologist. 25: e386-e390. PMID 32043767 DOI: 10.1634/Theoncologist.2019-0606  0.397
2020 Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV. New drug approvals in oncology. Nature Reviews. Clinical Oncology. PMID 32020042 DOI: 10.1038/S41571-019-0313-2  0.33
2020 Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 9: 1710052. PMID 32002305 DOI: 10.1080/2162402X.2019.1710052  0.34
2020 Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Al Baghdadi T, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, ... ... Kurzrock R, et al. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31969335 DOI: 10.1158/1078-0432.Ccr-19-3356  0.322
2020 Boichard A, Richard SB, Kurzrock R. The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. Cancers. 12. PMID 31936627 DOI: 10.3390/Cancers12010166  0.374
2020 Fontes Jardim DL, Millis SZ, Woo MS, Ross JS, Ali SM, Kurzrock R. Landscape of cyclin pathway genomic alterations across 7,207 non-prostate genitourinary tumors. Journal of Clinical Oncology. 38: 549-549. DOI: 10.1200/Jco.2020.38.6_Suppl.549  0.334
2020 Fontes Jardim DL, Millis SZ, Woo MS, Ross JS, Ali SM, Kurzrock R. Cyclin pathway genomic alterations across 5,356 prostate cancers. Journal of Clinical Oncology. 38: 179-179. DOI: 10.1200/Jco.2020.38.6_Suppl.179  0.317
2020 Shaya J, Randall JM, Millard FE, Kurzrock R, Parsons JK, Tamayo P, McKay RR. Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 110-110. DOI: 10.1200/Jco.2020.38.6_Suppl.110  0.338
2020 Glenn S, Pabla S, Kato S, Van Roey E, Conroy JM, Wang Y, Nesline M, Burgher B, Giamo V, Andreas J, Lenzo FL, Kurzrock R, Morrison C. Inflammation and cell proliferation signatures: Implications for response to immune checkpoint inhibition therapies. Journal of Clinical Oncology. 38: 67-67. DOI: 10.1200/Jco.2020.38.5_Suppl.67  0.33
2020 Shaya J, Kato S, Patel H, Fanta PT, Kurzrock R. Genomic-directed personalized matched targeted therapy approach may improve clinical outcomes among patients with advanced pancreatic cancer. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E16794  0.332
2020 Solomon BM, Callejo A, Bar J, Berchem GJ, Bazhenova L, Saintigny P, Raymond E, Girard N, Sulaiman R, Prouse B, Bresson C, Wunder F, Lee JJ, Raynaud J, Rubin E, ... ... Kurzrock R, et al. SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. Journal of Clinical Oncology. 38: 9581-9581. DOI: 10.1200/Jco.2020.38.15_Suppl.9581  0.374
2020 Gandara DR, Weipert C, Saam J, Riess JW, Lenz H, Kurzrock R. Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 38: 9523-9523. DOI: 10.1200/Jco.2020.38.15_Suppl.9523  0.34
2020 Shayeb AM, Kurzrock R, Kato S. Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies. Journal of Clinical Oncology. 38: 3632-3632. DOI: 10.1200/Jco.2020.38.15_Suppl.3632  0.35
2020 Adashek JJ, Kato S, Okamura R, Khalid N, Lee S, Nguyen VT, Sicklick JK, Kurzrock R. Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach. Journal of Clinical Oncology. 38: 3623-3623. DOI: 10.1200/Jco.2020.38.15_Suppl.3623  0.41
2020 Adams S, Othus M, Patel SP, Chae YK, Miller K, Chugh R, Schuetze S, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Kurzrock R. Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36). Journal of Clinical Oncology. 38: 1073-1073. DOI: 10.1200/Jco.2020.38.15_Suppl.1073  0.391
2020 Weipert C, Kato S, Saam J, Kurzrock R. Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy. Journal of Clinical Oncology. 38: 105-105. DOI: 10.1200/Jco.2020.38.15_Suppl.105  0.375
2020 Kurzrock R, Kato S. Abstract IA15: Liquid biopsies: Implications for therapeutic response/resistance and prognosis Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-Ia15  0.346
2020 Chae YK, Othus M, Patel SP, Zalupski M, Kasi A, Khalil M, Kalyan A, Polite B, Fenton S, Gurung S, McLeod CM, Giles F, Chen HX, Sharon E, Mayerson E, ... ... Kurzrock R, et al. Abstract 3417: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort Cancer Research. 80: 3417-3417. DOI: 10.1158/1538-7445.Am2020-3417  0.376
2019 Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DVT, Klevesath MB, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, et al. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31822497 DOI: 10.1158/1078-0432.Ccr-19-2860  0.341
2019 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Journal of Hematology & Oncology. 12: 130. PMID 31801585 DOI: 10.1186/S13045-019-0824-4  0.346
2019 Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, ... Kurzrock R, et al. Prognostic Implications of RAS Alterations in Diverse Malignancies and Impact of Targeted Therapies. International Journal of Cancer. PMID 31782524 DOI: 10.1002/Ijc.32813  0.33
2019 Li AM, Boichard A, Kurzrock R. Mutated is a marker of increased expression: analysis of 7,525 pan-cancer tissues. Cancer Biology & Therapy. 1-6. PMID 31564192 DOI: 10.1080/15384047.2019.1665956  0.378
2019 Falchook GS, Rosen S, LoRusso PM, Watts JM, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita MM, Cassaday RD, Harb W, Peguero JA, Smith DC, Piha-Paul SA, Szmulewitz RZ, et al. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31527168 DOI: 10.1158/1078-0432.Ccr-18-4071  0.316
2019 Adashek JJ, LoRusso PM, Hong DS, Kurzrock R. Phase I trials as valid therapeutic options for patients with cancer. Nature Reviews. Clinical Oncology. PMID 31477881 DOI: 10.1038/S41571-019-0262-9  0.344
2019 Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunology Research. PMID 31405947 DOI: 10.1158/2326-6066.Cir-19-0149  0.332
2019 Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. Genomic profiling of blood-derived circulating tumor DNA from patients with colorectal cancer: Implications for response and resistance to targeted therapeutics. Molecular Cancer Therapeutics. PMID 31320401 DOI: 10.1158/1535-7163.Mct-18-0965  0.408
2019 Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 10: 4018-4025. PMID 31258846 DOI: 10.18632/Oncotarget.26998  0.335
2019 Mardinian K, Okamura R, Kato S, Kurzrock R. Temporal and Spatial Effects and Survival Outcomes Associated with Concordance between Tissue and Blood KRAS Alterations in the Pan-Cancer Setting. International Journal of Cancer. PMID 31199507 DOI: 10.1002/Ijc.32510  0.311
2019 Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, et al. The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31186313 DOI: 10.1158/1078-0432.Ccr-18-1881  0.321
2019 Adashek JJ, Junior PNA, Galanina N, Kurzrock R. Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. Journal For Immunotherapy of Cancer. 7: 130. PMID 31113482 DOI: 10.1186/S40425-019-0618-9  0.351
2019 Janku F, Diamond EL, Goodman AM, Kandadai Raghavan V, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics. PMID 31015311 DOI: 10.1158/1535-7163.Mct-18-1244  0.366
2019 Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, ... ... Kurzrock R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine. PMID 31011206 DOI: 10.1038/S41591-019-0407-5  0.399
2019 Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, ... ... Kurzrock R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine. PMID 31011205 DOI: 10.1038/S41591-019-0424-4  0.377
2019 Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunology Research. PMID 31003990 DOI: 10.1158/2326-6066.Cir-18-0716  0.364
2019 Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. Next generation sequencing of tissue and circulating tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy experience with breast malignancies. Molecular Cancer Therapeutics. PMID 30926636 DOI: 10.1158/1535-7163.Mct-17-1038  0.344
2019 Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 30857956 DOI: 10.1016/S1470-2045(18)30904-5  0.351
2019 Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Framton GM, Tsigelny IF, Kurzrock R. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 8: 1550341. PMID 30723579 DOI: 10.1080/2162402X.2018.1550341  0.329
2019 Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, ... ... Kurzrock R, et al. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. Journal For Immunotherapy of Cancer. 7: 27. PMID 30709424 DOI: 10.1186/S40425-019-0506-3  0.315
2019 Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C. Novel patterns of response under immunotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30657859 DOI: 10.1093/Annonc/Mdz003  0.354
2019 Kurzrock R, Goldberg R, Ceacareanu AC, Wintrob ZAP. HSR19-096: The Impact of New Oncology Drugs on Disability and Health Care Spending: An Assessment of Real-World Evidence Journal of the National Comprehensive Cancer Network. 17: HSR19-096. DOI: 10.6004/Jnccn.2018.7253  0.319
2019 Goodman A, Pyke R, Kato S, Okamura R, Sokol E, Frampton GM, Miller VA, Carter H, Kurzrock R. MHC-1 genotype as a predictor of response to immunotherapy. Journal of Clinical Oncology. 37: 149-149. DOI: 10.1200/Jco.2019.37.8_Suppl.149  0.331
2019 Adashek JJ, Kato S, Parulkar R, Szeto C, Reddy SK, Kurzrock R. RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics. Journal of Clinical Oncology. 37: 583-583. DOI: 10.1200/Jco.2019.37.7_Suppl.583  0.339
2019 Patel SP, Othus M, Chae YK, Giles F, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. Journal of Clinical Oncology. 37: TPS2658-TPS2658. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2658  0.406
2019 Kato S, Porter R, Okamura R, Zelichov O, Tarcic G, Vidne M, Kurzrock R. A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients. Journal of Clinical Oncology. 37: 3071-3071. DOI: 10.1200/Jco.2019.37.15_Suppl.3071  0.34
2019 Kumaki Y, Ikeda S, Rich TA, Zhao J, Yoshino T, Cho BC, Peled N, Han J, Shiotsu Y, Franovic A, Raymond VM, Kurzrock R, Lanman RB, Lee J, Mok TSK. Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. Journal of Clinical Oncology. 37: 3046-3046. DOI: 10.1200/Jco.2019.37.15_Suppl.3046  0.341
2019 Janku F, Patel H, Kandadai Raghavan V, Goodman A, Barnes TG, Kurzrock R. MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis Blood. 134: 2319-2319. DOI: 10.1182/Blood-2019-126342  0.346
2019 Jensen TJ, Goodman AM, Kato S, Ellison CK, Kelly K, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, McLennan G, Almasri E, Grosu DS, Eisenberg M, ... Kurzrock R, et al. Abstract 1362: Genome-wide sequencing of cell-free DNA enables detection of copy number alterations in cancer patients where tissue biopsy is not feasible Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1362  0.314
2019 Patel SP, Othus M, Chae YK, Giles F, Hansel D, Singh P, Fontaine A, Shah M, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, MMcLeod C, ... ... Kurzrock R, et al. Abstract CT039: A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct039  0.387
2019 Nikanjam M, Arguello D, Gatalica Z, Barkauskas DA, Kurzrock R. Abstract 4928: Relationship between protein biomarkers of potential chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in patients with cancer Cancer Research. 79: 4928-4928. DOI: 10.1158/1538-7445.Am2019-4928  0.326
2018 Ikeda S, Kumaki Y, Rich TA, Shiotsu Y, Franovic A, Raymond VM, Kurzrock R, Lanman RB, Lee J, Mok TSK. Circulating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: ix116. PMID 32177748 DOI: 10.1093/Annonc/Mdy441.011  0.353
2018 Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast (Edinburgh, Scotland). 44: 29-32. PMID 30609392 DOI: 10.1016/J.Breast.2018.12.010  0.32
2018 Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers. 11. PMID 30583461 DOI: 10.3390/Cancers11010011  0.386
2018 Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer. PMID 30582752 DOI: 10.1002/Cncr.31921  0.335
2018 Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients. Molecular Cancer Therapeutics. PMID 30523049 DOI: 10.1158/1535-7163.Mct-18-0535  0.376
2018 Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. Journal For Immunotherapy of Cancer. 6: 119. PMID 30446007 DOI: 10.1186/S40425-018-0436-5  0.347
2018 Kato S, Kurzrock R. An avatar for precision cancer therapy. Nature Biotechnology. 36: 1053-1055. PMID 30412185 DOI: 10.1038/Nbt.4293  0.335
2018 Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Frontiers in Oncology. 8: 435. PMID 30386736 DOI: 10.3389/Fonc.2018.00435  0.311
2018 Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, ... ... Kurzrock R, et al. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. Cancer. PMID 30383888 DOI: 10.1002/Cncr.31812  0.371
2018 Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30348637 DOI: 10.1158/1078-0432.Ccr-18-1128  0.329
2018 Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, ... ... Kurzrock R, et al. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Jama Oncology. e183773. PMID 30347019 DOI: 10.1001/Jamaoncol.2018.3773  0.334
2018 Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biology & Therapy. 1-8. PMID 30339521 DOI: 10.1080/15384047.2018.1523849  0.349
2018 Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, ... ... Kurzrock R, et al. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800328. PMID 30339520 DOI: 10.1200/Jco.18.00328  0.354
2018 Jardim DL, de Melo Gagliato D, Kurzrock R. Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. Integrative Cancer Therapies. 1534735418801524. PMID 30229677 DOI: 10.1177/1534735418801524  0.361
2018 Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced Basal Cell Cancer: Concise Review of Molecular Characteristics and Novel Targeted and Immune Therapeutics. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30219896 DOI: 10.1093/Annonc/Mdy412  0.384
2018 Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. GNAS, GNAQ, and GNA11 Alterations in Patients With Diverse Cancers. Cancer. PMID 30204251 DOI: 10.1002/Cncr.31724  0.367
2018 Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunology Research. PMID 30194084 DOI: 10.1158/2326-6066.Cir-18-0121  0.319
2018 Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, et al. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. The Oncologist. PMID 30139837 DOI: 10.1634/Theoncologist.2017-0498  0.383
2018 Baumgartner JM, Raymond VM, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Annals of Surgical Oncology. PMID 29948422 DOI: 10.1245/S10434-018-6561-Z  0.345
2018 Ikeda S, Schwaederle M, Mohindra M, Fontes Jardim DL, Kurzrock R. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. Journal of Hematology & Oncology. 11: 76. PMID 29866143 DOI: 10.1186/S13045-018-0610-8  0.315
2018 Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, ... ... Kurzrock R, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer. PMID 29695765 DOI: 10.1038/S41416-018-0068-Z  0.364
2018 Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biology & Therapy. 1-17. PMID 29565699 DOI: 10.1080/15384047.2018.1450120  0.329
2018 Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, et al. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. British Journal of Cancer. PMID 29551775 DOI: 10.1038/S41416-018-0020-2  0.342
2018 Ikeda S, Lim JS, Kurzrock R. Analysis of Tissue and Circulating Tumor DNA by Next Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. PMID 29483209 DOI: 10.1158/1535-7163.Mct-17-0604  0.346
2018 Subbiah V, Kurzrock R. Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends in Cancer. 4: 101-109. PMID 29458960 DOI: 10.1016/J.Trecan.2017.12.004  0.31
2018 Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 7: e1404217. PMID 29399405 DOI: 10.1080/2162402X.2017.1404217  0.369
2018 Schrock AB, Pavlick DC, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordonii R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29363525 DOI: 10.1158/1078-0432.Ccr-17-3103  0.34
2018 Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753780. PMID 29320312 DOI: 10.1200/Jco.2017.75.3780  0.4
2018 Galanina N, Goodman A, Cohen PR, Kurzrock R. HIV-positive Kaposi sarcoma and immune checkpoint blockade. Journal of Clinical Oncology. 36: 63-63. DOI: 10.1200/Jco.2018.36.5_Suppl.63  0.313
2018 Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul SA, Janku F, Cartwright C, Broaddus R, Nogueras-Gonzalez GM, Hwu P, Kurzrock R. Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study. Journal of Clinical Oncology. 36: LBA2553-LBA2553. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba2553  0.326
2018 Nikanjam M, Arguello D, Gatalica Z, Barkauskas DA, Kurzrock R. Relationship between protein biomarkers of potential chemotherapy response and microsatellite status in 28,101 cancer patients. Journal of Clinical Oncology. 36: e24259-e24259. DOI: 10.1200/Jco.2018.36.15_Suppl.E24259  0.305
2018 Jensen TJ, Goodman A, Kato S, Ellison CK, Daniels GA, Tran L, McCarthy E, Nakashe P, Mazloom A, McLennan G, Grosu DS, Ehrich M, Kurzrock R. Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to enable genomic characterization that can be used to monitor immunotherapy response in cancer patients. Journal of Clinical Oncology. 36: e24050-e24050. DOI: 10.1200/Jco.2018.36.15_Suppl.E24050  0.36
2018 Tsimberidou AM, Verschraegen CF, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis JJ, Hicking C, Shaw J, Kaleta R, Kurzrock R. Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities. Journal of Clinical Oncology. 36: 2584-2584. DOI: 10.1200/Jco.2018.36.15_Suppl.2584  0.334
2018 Sicklick JK, Kato S, Schwaederle MC, Okamura R, Hahn M, Williams CB, De P, Krie AK, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, ... ... Kurzrock R, et al. Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy. Journal of Clinical Oncology. 36: 2531-2531. DOI: 10.1200/Jco.2018.36.15_Suppl.2531  0.345
2018 Okamura R, Kato S, Parulkar R, Szeto C, Reddy S, Kurzrock R. Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis. Journal of Clinical Oncology. 36: 12114-12114. DOI: 10.1200/Jco.2018.36.15_Suppl.12114  0.3
2018 Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Sicklick JK, Raymond VM, Lanman RB, Kurzrock R. Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers. Journal of Clinical Oncology. 36: 12028-12028. DOI: 10.1200/Jco.2018.36.15_Suppl.12028  0.351
2018 Rodon J, Soria J, Berger R, Miller WH, Lazar V, Rubin E, Tsimberidou AM, Saintigny P, Ackerstein A, Brana I, Loriot Y, Afshar M, Miller VA, Wunder F, Bresson C, ... ... Kurzrock R, et al. WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. Journal of Clinical Oncology. 36: 12011-12011. DOI: 10.1200/Jco.2018.36.15_Suppl.12011  0.325
2018 Galanina N, Jamieson C, Kurzrock R. Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies Blood. 132: 5116-5116. DOI: 10.1182/Blood-2018-99-119877  0.384
2018 Jensen TJ, Goodman AM, Ellison CK, Kato S, Daniels GA, Tran L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. Abstract 633: Application of a novel analytical metric that quantifies copy number alterations in low-coverage, genome-wide sequencing of cell-free DNA to monitor and differentiate response to immunotherapy in cancer patients Cancer Research. 78: 633-633. DOI: 10.1158/1538-7445.Am2018-633  0.387
2018 Boichard A, Pham TV, Richard SB, Kurzrock R. Abstract 2298: Understanding tumor biology complexity in the advanced cancer setting: PreciGENE® platform predictions correlate with exceptional responses to cancer treatment Cancer Research. 78: 2298-2298. DOI: 10.1158/1538-7445.Am2018-2298  0.393
2018 Schwaederle MC, Kato S, Choi IS, Fanta PT, Leichman L, Lippman S, Kurzrock R. Abstract LB-A07: Clinical utility of genomic assessment of blood-derived circulating tumor (ctDNA) in patients with colorectal cancers Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A07  0.415
2017 Kurzrock R, Hickish T, Wyrwicz L, André T, Sarosiek T, Kocsis J, Nemecek R, Wu Q, Mohanty P, Stecher M, Simard J, Dinarello C. Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii98-iii99. PMID 32136086 DOI: 10.1093/Annonc/Mdx261.280  0.316
2017 Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29212781 DOI: 10.1158/1078-0432.Ccr-17-1970  0.361
2017 Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. PMID 29211306 DOI: 10.1002/Cncr.31175  0.364
2017 Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. Molecular Cancer Therapeutics. 16: 2645-2655. PMID 29203694 DOI: 10.1158/1535-7163.Mct-17-0597  0.345
2017 Patel M, Kato SM, Kurzrock R. Molecular Tumor Boards: Realizing Precision Oncology Therapy. Clinical Pharmacology and Therapeutics. PMID 29134641 DOI: 10.1002/Cpt.920  0.316
2017 Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. Molecular Cancer Therapeutics. PMID 29133621 DOI: 10.1200/Jco.2017.35.15_Suppl.11574  0.391
2017 Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, ... ... Kurzrock R, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. Jco Precision Oncology. 2017. PMID 29082359 DOI: 10.1200/PO.17.00002  0.365
2017 Kato S, Kurasaki K, Ikeda S, Kurzrock R. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. The Oncologist. PMID 29038235 DOI: 10.1634/Theoncologist.2017-0199  0.361
2017 Kato S, Kurzrock R. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 6376. PMID 29030333 DOI: 10.1158/1078-0432.Ccr-17-1990  0.347
2017 Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 5729-5736. PMID 28972084 DOI: 10.1158/1078-0432.Ccr-17-1439  0.372
2017 Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. Next-generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Research. PMID 28939679 DOI: 10.1158/0008-5472.Can-17-1569  0.384
2017 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Molecular Cancer. 16: 149. PMID 28854942 DOI: 10.1186/S12943-017-0712-X  0.335
2017 Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular Cancer Therapeutics. PMID 28835386 DOI: 10.1158/1535-7163.Mct-17-0386  0.3
2017 Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Research. PMID 28807936 DOI: 10.1158/0008-5472.Can-17-0885  0.397
2017 Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. International Journal of Molecular Sciences. 18. PMID 28788102 DOI: 10.3390/Ijms18081663  0.36
2017 Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. European Journal of Cancer (Oxford, England : 1990). 83: 229-236. PMID 28755607 DOI: 10.1016/J.Ejca.2017.06.018  0.328
2017 Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, et al. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28729355 DOI: 10.1158/1078-0432.Ccr-16-3027  0.316
2017 Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. European Journal of Cancer (Oxford, England : 1990). 83: 80-87. PMID 28728050 DOI: 10.1016/J.Ejca.2017.06.019  0.343
2017 Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. Jco Precision Oncology. 1: 1-13. PMID 28681041 DOI: 10.1182/Blood.V128.22.5291.5291  0.354
2017 Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Research. PMID 28642281 DOI: 10.1158/0008-5472.Can-17-0628  0.388
2017 Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. The Oncologist. PMID 28550027 DOI: 10.1634/Theoncologist.2016-0517  0.39
2017 Schwaederle M, Patel SP, Husain H, Ikeda M, Lanman R, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28539465 DOI: 10.1158/1078-0432.Ccr-16-2497  0.397
2017 Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Molecular Cancer Therapeutics. 16: 948-955. PMID 28468865 DOI: 10.1158/1535-7163.Mct-16-0436  0.365
2017 Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. The Oncologist. PMID 28424323 DOI: 10.1634/Theoncologist.2016-0357  0.359
2017 Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen EEW, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420725 DOI: 10.1158/1078-0432.Ccr-17-0454  0.384
2017 Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28377484 DOI: 10.1158/1078-0432.Ccr-17-0272  0.353
2017 Kato S, Goodman AM, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28351930 DOI: 10.1158/1078-0432.Ccr-16-3133  0.353
2017 Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ. Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. Cancer Treatment Reviews. 55: 10-15. PMID 28279895 DOI: 10.1016/J.Ctrv.2017.02.006  0.349
2017 Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Investigational New Drugs. PMID 28194539 DOI: 10.1007/S10637-017-0442-3  0.393
2017 Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. Molecular Cancer Therapeutics. 16: 265-272. PMID 28159915 DOI: 10.1158/1535-7163.Mct-16-0105  0.356
2017 Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer. PMID 28103611 DOI: 10.1038/Bjc.2016.419  0.325
2017 Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Guo S, Yoo B, Beattie MS, Tayama D, Sweeney C. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 348-348. DOI: 10.1200/Jco.2017.35.6_Suppl.348  0.356
2017 Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Vanderwalde AM, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Bernaards C, Beattie MS, Sommer N, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. 35: 676-676. DOI: 10.1200/Jco.2017.35.4_Suppl.676  0.418
2017 Javle MM, Hainsworth JD, Swanton C, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Spigel DR, Bose R, Guo S, Bernaards C, Beattie MS, Scappaticci FA, Hurwitz H. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 402-402. DOI: 10.1200/Jco.2017.35.4_Suppl.402  0.424
2017 Ikeda S, Lim JS, Kurzrock R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma. Journal of Clinical Oncology. 35: 298-298. DOI: 10.1200/Jco.2017.35.4_Suppl.298  0.336
2017 Subbiah IM, Tang C, Rao A, Subbiah V, Kurzrock R, Hong DS. Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents. Journal of Clinical Oncology. 35: 149-149. DOI: 10.1200/Jco.2017.35.31_Suppl.149  0.336
2017 Soria J, Rodon Ahnert J, Berger R, Miller WH, Brana I, Loriot Y, Mughal TI, Lazar V, Wunder F, Bresson C, Koscielny S, Afshar M, Saintigny P, Tsimberidou AM, Richon C, ... ... Kurzrock R, et al. WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. Journal of Clinical Oncology. 35: TPS11625-TPS11625. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps11625  0.386
2017 Galanina N, Goodman A, Tran L, Bejar R, Choi MY, Kurzrock R. Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies. Journal of Clinical Oncology. 35: e23133-e23133. DOI: 10.1200/Jco.2017.35.15_Suppl.E23133  0.316
2017 Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients in cancer clinical trials. Journal of Clinical Oncology. 35: e14620-e14620. DOI: 10.1200/Jco.2017.35.15_Suppl.E14620  0.335
2017 Goodman A, Jensen T, Kato S, Ellison C, Tran L, Mazloom A, Grosu DS, Ehrich M, Kurzrock R. Serial genome-wide sequencing of cell-free DNA (cfDNA) by assays used in non-invasive prenatal testing (NIPT) to identify copy number alterations (CNAs) associated with immunotherapy response. Journal of Clinical Oncology. 35: e14533-e14533. DOI: 10.1200/Jco.2017.35.15_Suppl.E14533  0.353
2017 Goodman A, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller VA, Stephens P, Kurzrock R. Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers. Journal of Clinical Oncology. 35: e14508-e14508. DOI: 10.1200/Jco.2017.35.15_Suppl.E14508  0.321
2017 Khagi Y, Goodman A, Daniels GA, Patel SP, Bazhenova L, Kurzrock R. Total number of circulating tumor DNA (ctDNA) genomic alterations and outcome after checkpoint inhibitor-based immunotherapy. Journal of Clinical Oncology. 35: e14504-e14504. DOI: 10.1200/Jco.2017.35.15_Suppl.E14504  0.373
2017 Lanman TA, Kesari S, Patel SP, Bazhenova L, Parker BA, Daniels GA, Fanta PT, Plaxe SC, Schwaederle MC, Kurzrock R, Piccioni DE. Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 35: e13546-e13546. DOI: 10.1200/Jco.2017.35.15_Suppl.E13546  0.326
2017 Hainsworth JD, Bose R, Sweeney C, Meric-Bernstam F, Hurwitz H, Swanton C, Burris HA, Kurzrock R, Yoo B, Beattie MS, Gupta R, Patel RD, Schulze K, Spigel DR. Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 9073-9073. DOI: 10.1200/Jco.2017.35.15_Suppl.9073  0.38
2017 Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 6086-6086. DOI: 10.1200/Jco.2017.35.15_Suppl.6086  0.425
2017 Maitland ML, Sharma M, Zhao B, McKee MD, Karovic S, Thomeas V, McIver M, Yang H, Piha-Paul SA, Falchook GS, Karrison T, Kurzrock R, Janisch LA, Hoening E, Wong S, et al. Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib. Journal of Clinical Oncology. 35: 2563-2563. DOI: 10.1200/Jco.2017.35.15_Suppl.2563  0.335
2017 Sen S, Piha-Paul SA, Kato S, Karp DD, Janku F, Fu S, Naing A, Pant S, Tsimberidou AM, Subbiah V, Kurzrock R, Meric-Bernstam F, Hong DS. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers. Journal of Clinical Oncology. 35: 2526-2526. DOI: 10.1200/Jco.2017.35.15_Suppl.2526  0.334
2017 Sicklick JK, Leyland-Jones B, Kato S, Hahn M, Williams C, De P, Miller VA, Ross JS, Benson A, Webster J, Stephens P, Scur M, Porter R, Tran L, Jepperson SH, ... ... Kurzrock R, et al. Personalized, molecularly matched combination therapies for treatment-na. Journal of Clinical Oncology. 35: 2512-2512. DOI: 10.1200/Jco.2017.35.15_Suppl.2512  0.391
2017 Slavin TP, Banks K, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek M, Lilly MB, Sonpavde G, ... ... Kurzrock R, et al. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. Journal of Clinical Oncology. 35: 1514-1514. DOI: 10.1200/Jco.2017.35.15_Suppl.1514  0.367
2017 Schwaederle MC, Chattopadhyay R, Kato S, Fanta PT, Banks K, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Journal of Clinical Oncology. 35: 11593-11593. DOI: 10.1200/Jco.2017.35.15_Suppl.11593  0.382
2017 Kato S, Kurasaki K, Ikeda S, Kurzrock R. Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach. Journal of Clinical Oncology. 35: 11578-11578. DOI: 10.1200/Jco.2017.35.15_Suppl.11578  0.357
2017 Kato S, Krishnamurthy N, Banks K, Williams KA, Williams CB, Leyland-Jones B, Lanman RB, Kurzrock R. Genomic analysis of circulating tumor DNA in 442 patients with carcinoma of unknown primary: Implications for targeted therapeutics. Journal of Clinical Oncology. 35: 11511-11511. DOI: 10.1200/Jco.2017.35.15_Suppl.11511  0.389
2017 Shatsky R, Parker B, Schwab R, Helsten T, Boles S, Subramanian R, Piccioni D, Kurzrock R. Abstract P1-07-15: Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-07-15  0.414
2017 Sicklick JK, Leyland-Jones B, Kato S, Williams C, De P, Heestand G, Plaxe S, Solomon B, Miller V, Benson A, Webster J, Ross J, Scur M, Porter R, Jepperson S, ... ... Kurzrock R, et al. Abstract CT053: High rates of personalized molecular matching are achievable in a precision oncology navigation trial: the I-PREDICT study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct053  0.381
2017 Ellison CK, Goodman AM, Riethdorf S, Mazloom AR, Tran L, Nakashe P, McCarthy E, Gorges T, Stein A, Quidde J, Grosu DS, Ehrich M, Jensen TJ, Pantel K, Kurzrock R. Abstract 5693: Low coverage genome-wide sequencing of cell-free DNA enables detection, therapeutic monitoring, and characterization of copy number alterations in patients with solid tumors Cancer Research. 77: 5693-5693. DOI: 10.1158/1538-7445.Am2017-5693  0.317
2017 Tsimberidou A, Verschraegen C, Weise A, Sarantopoulos J, Lopes G, Nemunaitis J, Victor A, Shaw J, Kaleta R, Kurzrock R. Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer Annals of Oncology. 28: v123. DOI: 10.1093/Annonc/Mdx367.004  0.359
2016 Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, ... ... Kurzrock R, et al. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. Journal of Translational Medicine. 14: 339. PMID 27974047 DOI: 10.1186/S12967-016-1075-6  0.331
2016 Kurzrock R, Stewart DJ. Exploring the Benefit/Risk Associated With Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27940520 DOI: 10.1158/1078-0432.Ccr-16-1968  0.351
2016 Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, ... ... Kurzrock R, et al. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. Jama Oncology. PMID 27893038 DOI: 10.1001/Jamaoncol.2016.5281  0.329
2016 Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Reviews. PMID 27873079 DOI: 10.1007/S10555-016-9652-Y  0.34
2016 Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852698 DOI: 10.1158/1078-0432.Ccr-16-1936  0.301
2016 Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27683183 DOI: 10.1158/1078-0432.Ccr-16-1679  0.346
2016 Janku F, Kurzrock R. Bringing Blood-Based Molecular Testing to the Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663595 DOI: 10.1158/1078-0432.Ccr-16-1769  0.338
2016 Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. International Journal of Cancer. PMID 27599876 DOI: 10.1002/Ijc.30417  0.398
2016 Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, ... ... Kurzrock R, et al. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. PMID 27589687 DOI: 10.18632/Oncotarget.11750  0.365
2016 Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Genomic Landscape of Malignant Mesotheliomas. Molecular Cancer Therapeutics. PMID 27507853 DOI: 10.1200/Jco.2016.34.15_Suppl.8555  0.367
2016 Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. PMID 27486883 DOI: 10.18632/Oncotarget.10910  0.325
2016 Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, ... ... Kurzrock R, et al. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors:Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. PMID 27466356 DOI: 10.1158/1535-7163.Mct-16-0196  0.391
2016 Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Molecular Cancer Therapeutics. PMID 27413114 DOI: 10.1158/1535-7163.Mct-15-0945  0.344
2016 Nikanjam M, Liu S, Kurzrock R. Dosing Targeted and Cytotoxic Two-Drug Combinations: Lessons Learned from Analysis of 24,326 Patients Reported 2010 through 2013. International Journal of Cancer. PMID 27389805 DOI: 10.1002/Ijc.30262  0.302
2016 Lam LH, Capparelli EV, Kurzrock R. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemotherapy and Pharmacology. PMID 27372908 DOI: 10.1007/S00280-016-3087-6  0.306
2016 Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. Jama Oncology. PMID 27273579 DOI: 10.1001/Jamaoncol.2016.2129  0.314
2016 Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, ... ... Kurzrock R, et al. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics. PMID 27207774 DOI: 10.1158/1535-7163.Mct-15-0712  0.373
2016 Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner RG, Subbiah V, Fu S, Karp DD, Falchook GS, Tsimberidou AM, Piha-Paul SA, Anderson R, Ke D, Miller VA, ... ... Kurzrock R, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Research. PMID 27197177 DOI: 10.1158/0008-5472.Can-15-3043  0.391
2016 Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Cell cycle gene alterations in 4864 tumors analyzed by next generation sequencing:  Implications for targeted therapeutics. Molecular Cancer Therapeutics. PMID 27196769 DOI: 10.1158/1535-7163.Mct-16-0071  0.371
2016 Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185373 DOI: 10.1158/1078-0432.Ccr-16-0318  0.36
2016 Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. PMID 27085994 DOI: 10.1007/S00280-016-3000-3  0.389
2016 Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. Journal of the National Cancer Institute. 108. PMID 27059373 DOI: 10.1093/Jnci/Djw036  0.367
2016 Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, et al. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27044938 DOI: 10.1200/Jco.2015.64.5788  0.333
2016 Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics. PMID 27009213 DOI: 10.1158/1535-7163.Mct-15-0643  0.387
2016 Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget. PMID 26981779 DOI: 10.18632/Oncotarget.8032  0.385
2016 Parsons HA, Baracos VE, Hong DS, Abbruzzese J, Bruera E, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. PMID 26934122 DOI: 10.18632/Oncotarget.7773  0.314
2016 Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. PMID 26933802 DOI: 10.18632/Oncotarget.7594  0.335
2016 Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. PMID 26873727 DOI: 10.1158/1535-7163.MCT-15-0795  0.351
2016 Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Reviews. 35: 263-75. PMID 26857926 DOI: 10.1007/S10555-016-9602-8  0.37
2016 Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. PMID 26848768 DOI: 10.18632/oncotarget.7110  0.327
2016 Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. PMID 26824502 DOI: 10.18632/Oncotarget.7023  0.307
2016 Kurzrock R, Stewart DJ. Click chemistry, 3D-printing, and omics: the future of drug development. Oncotarget. 7: 2155-8. PMID 26734837 DOI: 10.18632/Oncotarget.6787  0.308
2016 Jardim DLF, Schwaederle M, Wei M, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Erratum: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval (Journal of the National Cancer Institute (2015) 107:11 (djv253) DOI:10.1093/jnci/djv253) Journal of the National Cancer Institute. 108. PMID 26727926 DOI: 10.1093/Jnci/Djv423  0.303
2016 Fajgenbaum DC, Kurzrock R. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy. 8: 17-26. PMID 26634298 DOI: 10.2217/Imt.15.95  0.316
2016 Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris HA, Bose R, Guo S, Bernaards C, Beattie MS, Stein A, Brammer M, Kurzrock R. Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. Journal of Clinical Oncology. 34: LBA11511-LBA11511. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba11511  0.37
2016 Zill OA, Mortimer S, Banks KC, Nagy RJ, Chudova D, Jackson C, Baca A, Ye JZ, Lanman RB, Talasaz A, Eltoukhy H, Kurzrock R. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. Journal of Clinical Oncology. 34: LBA11501-LBA11501. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba11501  0.377
2016 Schwaederle MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma. Journal of Clinical Oncology. 34: e23097-e23097. DOI: 10.1200/Jco.2016.34.15_Suppl.E23097  0.304
2016 Baumgartner JM, Banks KC, Lanman RB, Tran L, Kelly KJ, Lowy AM, Kurzrock R. Circulating tumor DNA before and after surgical resection in patients with peritoneal carcinomatosis. Journal of Clinical Oncology. 34: e13000-e13000. DOI: 10.1200/Jco.2016.34.15_Suppl.E13000  0.345
2016 Nikanjam M, Liu S, Kurzrock R. Dosing de novo two-drug combinations based on 32,894 patients in phase I-III clinical trials. Journal of Clinical Oncology. 34: 2563-2563. DOI: 10.1200/Jco.2016.34.15_Suppl.2563  0.321
2016 Faiq N, Patel SP, Bazhenova L, Parker BA, Plaxe SC, Kurzrock R, Kesari S, Piccioni DE. Characterization of cell-free circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 34: 2023-2023. DOI: 10.1200/Jco.2016.34.15_Suppl.2023  0.336
2016 Schwaederle MC, Zhao MM, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials. Journal of Clinical Oncology. 34: 11520-11520. DOI: 10.1200/Jco.2016.34.15_Suppl.11520  0.345
2016 Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Kurzrock R, Karp DD, Hong DS. Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients. Journal of Clinical Oncology. 34: 10049-10049. DOI: 10.1200/Jco.2016.34.15_Suppl.10049  0.323
2016 Husain H, Kosco K, Hancock S, Samuelsz E, Guerrero S, Woodward B, Vibat CR, Melnikova V, Erlander M, Lippman S, Kurzrock R. Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response Clinical Cancer Research. 22: 30-30. DOI: 10.1158/1557-3265.Pmsclingen15-30  0.389
2016 Basho R, Gilcrease M, Murthy R, Helgason T, Booser D, Karp D, Meric-Bernstam F, Wheler J, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim N, Murray J, Koenig K, ... ... Kurzrock R, et al. Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-14-02  0.386
2016 Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, ... ... Kurzrock R, et al. Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response Cancer Research. 76: 2273-2273. DOI: 10.1158/1538-7445.Am2016-2273  0.417
2015 Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R&D. PMID 26689566 DOI: 10.1007/S40268-015-0114-8  0.324
2015 Liu S, Kurzrock R. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Seminars in Oncology. 42: 863-875. PMID 26615131 DOI: 10.1053/J.Seminoncol.2015.09.032  0.305
2015 Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Seminars in Oncology. 42: 832-48. PMID 26615129 DOI: 10.1053/J.Seminoncol.2015.09.022  0.337
2015 Munster PN, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, Agarwal N, Kleha JF, Durante M, Adams LM, Smith DA, ... ... Kurzrock R, et al. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26603258 DOI: 10.1158/1078-0432.Ccr-15-1665  0.342
2015 Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Science Translational Medicine. 7: 314ra185. PMID 26582900 DOI: 10.1126/Scitranslmed.Aac5272  0.378
2015 Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1337-46. PMID 26553764 DOI: 10.6004/Jnccn.2015.0163  0.333
2015 Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. Bmc Cancer. 15: 713. PMID 26474549 DOI: 10.1186/S12885-015-1701-3  0.312
2015 Stewart DJ, Batist G, Kantarjian HM, Bradford JP, Schiller JH, Kurzrock R. The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4561-8. PMID 26473192 DOI: 10.1158/1078-0432.Ccr-14-3246  0.308
2015 Jain RK, Hong DS, Naing A, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel Phase I Study Combining G1 Phase, S Phase, and G2/M Phase Cell Cycle Inhibitors in Patients with Advanced Malignancies. Cell Cycle (Georgetown, Tex.). 0. PMID 26467427 DOI: 10.1080/15384101.2015.1090065  0.301
2015 Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. Seminars in Oncology. 42: 731-9. PMID 26433554 DOI: 10.1053/J.Seminoncol.2015.07.010  0.346
2015 Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. PMID 26418953 DOI: 10.18632/Oncotarget.5289  0.373
2015 Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, ... ... Kurzrock R, et al. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6: 24581. PMID 26405159 DOI: 10.18632/Oncotarget.5663  0.369
2015 Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26392102 DOI: 10.1200/Jco.2015.63.2471  0.341
2015 Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26373574 DOI: 10.1158/1078-0432.Ccr-14-3212  0.415
2015 Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, ... ... Kurzrock R, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. PMID 26330075 DOI: 10.18632/Oncotarget.4723  0.32
2015 Rhee FV, Casper C, Voorhees PM, Fayad LE, Velde HV, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. PMID 26327301 DOI: 10.18632/Oncotarget.4655  0.35
2015 Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304871 DOI: 10.1200/Jco.2015.61.5997  0.348
2015 Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. Genomic landscape of salivary gland tumors. Oncotarget. PMID 26247885 DOI: 10.1200/Jco.2015.33.15_Suppl.6056  0.398
2015 Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. Journal of Oncology Practice / American Society of Clinical Oncology. PMID 26243651 DOI: 10.1200/Jop.2015.004127  0.402
2015 Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Reviews. 34: 479-96. PMID 26224133 DOI: 10.1007/S10555-015-9579-8  0.359
2015 Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 76: 597-603. PMID 26210681 DOI: 10.1007/S00280-015-2824-6  0.367
2015 Khemlina G, Ikeda S, Kurzrock R. Molecular landscape of prostate cancer: Implications for current clinical trials. Cancer Treatment Reviews. 41: 761-6. PMID 26210103 DOI: 10.1016/J.Ctrv.2015.07.001  0.34
2015 Hong D, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26169970 DOI: 10.1158/1078-0432.Ccr-14-3063  0.356
2015 Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 6: 18693-706. PMID 26155941 DOI: 10.18632/Oncotarget.4472  0.331
2015 Ikeda S, Hansel DE, Kurzrock R. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treatment Reviews. 41: 699-706. PMID 26138514 DOI: 10.1016/J.Ctrv.2015.06.004  0.3
2015 Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 53: 563-72. PMID 26073352 DOI: 10.5414/Cp202359  0.332
2015 Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. The Oncologist. 20: 737-41. PMID 26054632 DOI: 10.1634/Theoncologist.2015-0065  0.349
2015 Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle (Georgetown, Tex.). 1-7. PMID 26030731 DOI: 10.1200/Jco.2015.33.15_Suppl.11099  0.389
2015 Kurzrock R, Giles FJ. Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle (Georgetown, Tex.). 14: 2219-21. PMID 26030337 DOI: 10.1080/15384101.2015.1041695  0.373
2015 Wheler JJ, Atkins JT, Janku F, Moulder SL, Yelensky R, Stephens PJ, Kurzrock R. Multiple gene aberrations and breast cancer: lessons from super-responders. Bmc Cancer. 15: 442. PMID 26021831 DOI: 10.1186/S12885-015-1439-Y  0.308
2015 Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, ... ... Kurzrock R, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6: 12809-21. PMID 25980577 DOI: 10.18632/Oncotarget.3373  0.365
2015 Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle (Georgetown, Tex.). 14: 2121-8. PMID 25950492 DOI: 10.1080/15384101.2015.1041691  0.355
2015 Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, ... ... Kurzrock R, et al. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. PMID 25944621 DOI: 10.18632/Oncotarget.3741  0.328
2015 Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle (Georgetown, Tex.). 14: 1730-7. PMID 25928476 DOI: 10.1080/15384101.2015.1033596  0.327
2015 Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 25908602 DOI: 10.1093/Annonc/Mdv191  0.351
2015 Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, ... Kurzrock R, et al. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs. 33: 700-9. PMID 25902899 DOI: 10.1200/Jco.2015.33.15_Suppl.2588  0.387
2015 Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. Bmc Cancer. 15: 61. PMID 25886620 DOI: 10.1186/S12885-015-1029-Z  0.323
2015 Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1346-52. PMID 25878190 DOI: 10.1093/Annonc/Mdv163  0.373
2015 Cohen PR, Kurzrock R. Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. Dermatology and Therapy. 5: 129-43. PMID 25876211 DOI: 10.1007/S13555-015-0074-5  0.32
2015 Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Molecular Cancer Therapeutics. 14: 1488-94. PMID 25852059 DOI: 10.1158/1535-7163.Mct-14-1061  0.37
2015 Falchook GS, Kurzrock R. VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle (Georgetown, Tex.). 14: 1129-30. PMID 25845022 DOI: 10.1080/15384101.2015.1022071  0.428
2015 Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33: 621-31. PMID 25822109 DOI: 10.1007/S10637-015-0226-6  0.351
2015 Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7: 29. PMID 25806091 DOI: 10.1186/S13148-015-0065-5  0.365
2015 Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 6: 6029-39. PMID 25760241 DOI: 10.18632/Oncotarget.3472  0.371
2015 Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 6: 4553-61. PMID 25714017 DOI: 10.18632/Oncotarget.2972  0.379
2015 Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Reviews. 34: 157-64. PMID 25712293 DOI: 10.1007/S10555-015-9552-6  0.373
2015 Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle (Georgetown, Tex.). 14: 1252-9. PMID 25695927 DOI: 10.1080/15384101.2015.1014149  0.384
2015 Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, ... ... Kurzrock R, et al. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. Journal of the National Cancer Institute. 107. PMID 25688104 DOI: 10.1093/Jnci/Dju493  0.356
2015 Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 25680763 DOI: 10.1007/S00520-015-2625-9  0.319
2015 Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Research. 75: 1187-90. PMID 25672981 DOI: 10.1158/0008-5472.Can-14-2305  0.399
2015 Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, ... ... Kurzrock R, et al. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1012-8. PMID 25669829 DOI: 10.1093/Annonc/Mdv066  0.329
2015 Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 75: 869-74. PMID 25666183 DOI: 10.1007/S00280-015-2695-X  0.318
2015 Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 6: 3033-42. PMID 25596748 DOI: 10.18632/Oncotarget.2848  0.334
2015 Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 6: 592-603. PMID 25595907 DOI: 10.18632/Oncotarget.2831  0.332
2015 Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Investigational New Drugs. 33: 215-24. PMID 25363205 DOI: 10.1007/S10637-014-0176-4  0.322
2015 Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, ... ... Kurzrock R, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discovery. 5: 64-71. PMID 25324352 DOI: 10.1182/Blood.V124.21.1833.1833  0.373
2015 Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational New Drugs. 33: 177-86. PMID 25323060 DOI: 10.1007/S10637-014-0173-7  0.362
2015 Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 25: 71-7. PMID 25285888 DOI: 10.1089/Thy.2014.0123  0.322
2015 Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, et al. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clinical Genitourinary Cancer. 13: e19-26. PMID 25087088 DOI: 10.1016/J.Clgc.2014.06.017  0.32
2015 Heestand GM, Schwaederle MC, Arguello D, Reddy SK, Gatalica Z, Kurzrock R. Topoisomerase expression in solid tumors: Analysis of 24,262 patient specimens. Journal of Clinical Oncology. 33: e22077-e22077. DOI: 10.1200/Jco.2015.33.15_Suppl.E22077  0.317
2015 Randall JM, Erlander MG, Vibat CRT, Hancock S, Melnikova V, Cohen EEW, Lippman SM, Kurzrock R, Husain H. Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma. Journal of Clinical Oncology. 33: e19092-e19092. DOI: 10.1200/Jco.2015.33.15_Suppl.E19092  0.311
2015 Husain H, Phallen J, Parpart-Li S, Murphy DM, Adleff V, Angiuoli SV, Jones S, Cohen EEW, Lippman SM, Diaz LA, Sausen M, Kurzrock R, Velculescu VE. A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients. Journal of Clinical Oncology. 33: e19082-e19082. DOI: 10.1200/Jco.2015.33.15_Suppl.E19082  0.304
2015 Husain H, Kosco K, Vibat CRT, Melnikova V, Erlander MG, Cohen EEW, Lippman SM, Kurzrock R. Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. Journal of Clinical Oncology. 33: 8081-8081. DOI: 10.1200/Jco.2015.33.15_Suppl.8081  0.359
2015 Mendelsohn J, Lazar V, Rubin E, Pawitan Y, Bresson C, Soria J, Eggermont A, Wunder F, Scoazec J, Hong WK, Blay J, Schilsky RL, Kurzrock R. Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 7524-7524. DOI: 10.1200/Jco.2015.33.15_Suppl.7524  0.324
2015 Falchook GS, Kurzrock R, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng H, Sarholz B, Johne A, Hong DS. Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J). Journal of Clinical Oncology. 33: 2591-2591. DOI: 10.1200/Jco.2015.33.15_Suppl.2591  0.344
2015 Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberidou AM, Kaseb AO, Oki Y, Zinner R, Patel S, Velez Bravo VM, ... ... Kurzrock R, et al. Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. Journal of Clinical Oncology. 33: 2584-2584. DOI: 10.1200/Jco.2015.33.15_Suppl.2584  0.371
2015 Faiq N, Chmielecki J, Goldberg M, Stephens P, Kurzrock R, Kesari S, Piccioni DE. Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. Journal of Clinical Oncology. 33: 2074-2074. DOI: 10.1200/Jco.2015.33.15_Suppl.2074  0.322
2015 Schwaederle MC, Zhao MM, Lee JJ, Eggermont A, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. Journal of Clinical Oncology. 33: 11097-11097. DOI: 10.1200/Jco.2015.33.15_Suppl.11097  0.351
2015 Wheler JJ, Yelensky R, Stephen B, Hong DS, Zinner R, Subbiah V, Fu S, Karp DD, Falchook GS, Naing A, Tsimberidou AM, Piha-Paul SA, Janku F, Li Y, Lee JJ, ... ... Kurzrock R, et al. Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. Journal of Clinical Oncology. 33: 11019-11019. DOI: 10.1200/Jco.2015.33.15_Suppl.11019  0.37
2015 Kato S, Janku F, Piha-Paul SA, Naing A, Karp DD, Tsimberidou AM, Subbiah V, Zinner R, Hwu W, Javle MM, Parkhurst KL, Ramzanali NM, Kurzrock R, Meric-Bernstam F, Chae YK, et al. Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer. Journal of Clinical Oncology. 33: 105-105. DOI: 10.1200/Jco.2015.33.15_Suppl.105  0.313
2015 Gatalica Z, Millis SZ, Xiu J, Arguello D, Feldman R, Kurzrock R. Abstract B18: PI3K/mTOR pathway aberrations across diverse solid tumors: Analysis of 13,500 patients Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-B18  0.405
2015 Wheler JJ, Janku F, Moulder SL, Naing A, Piha-Paul SA, Falchook GS, Zinner RG, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Miller V, Stephens PJ, Valero V, ... ... Kurzrock R, et al. Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-05-03  0.395
2015 Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Abstract 4957: Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer Cancer Research. 75: 4957-4957. DOI: 10.1158/1538-7445.Am2015-4957  0.353
2015 Kato S, Naing A, Falchook G, Holley VR, Velez-Bravo VM, Patel S, Zinner RG, Piha-Paul SA, Tsimberidou AM, Hong DS, Kurzrock R, Meric-Bernstam F, Janku F. Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study Cancer Research. 75: 2689-2689. DOI: 10.1158/1538-7445.Am2015-2689  0.403
2015 Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Tsimberidou AM, Hong DS, Naing A, Wheler JJ, Piha-Paul SA, Karp DD, Subbiah V, Zinner RG, Ramzanali N, Luthra R, ... ... Kurzrock R, et al. Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform Cancer Research. 75: 2413-2413. DOI: 10.1158/1538-7445.Am2015-2413  0.383
2015 Husain H, Venkatapathy S, Gomez G, Woodward B, Lee S, Khambaty L, Chen L, Duttagupta R, Fung ET, Kurzrock R. Abstract 2410: Cell-free DNA derived from ascites: Detection of copy number and somatic mutations using OncoScan FFPE® Assay Cancer Research. 75: 2410-2410. DOI: 10.1158/1538-7445.Am2015-2410  0.356
2015 Schwaederle MC, Piccioni DE, Kesari S, Husain H, Patel SP, Kurzrock R. Abstract C19: Use of liquid biopsies in clinical oncology: the UCSD Moores Cancer Center experience in 168 patients with diverse malignancies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C19  0.405
2015 Ikeda S, Banks K, Lanman RB, Kurzrock R. Abstract C149: Next-generation sequencing of biopsy-free circulating tumor DNA revealed frequent actionable alterations in advanced hepatocellular carcinoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C149  0.403
2015 Tsimberidou A, Verschraegen C, Heestand G, Kaleta R, Scheuenpflug J, Huck B, Weise A, Kurzrock R. A first in human, dose escalation trial of MSC2363318A – a dual p70S6K/Akt inhibitor, for patients with advanced malignancies Annals of Oncology. 26: ii25. DOI: 10.1093/Annonc/Mdv094.1  0.417
2015 Husain H, Melnikova V, Kosco K, Hancock S, Samuelsz E, Woodward B, Guerrero S, Vibat C, Erlander M, Cohen E, Lippman S, Kurzrock R. 3136 Kinetic monitoring of EGFR and KRAS mutations in urinary circulating tumor DNA predicts radiographic progression and response in patients with metastatic lung adenocarcinoma European Journal of Cancer. 51: S648-S649. DOI: 10.1016/S0959-8049(16)31777-4  0.327
2014 Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng H, Bladt F, Johne A, Kurzrock R. 450PDFIRST-IN-HUMAN PHASE I TRIAL ASSESSING THE HIGHLY SELECTIVE C-MET INHIBITOR MSC2156119J (EMD 1214063) IN PATIENTS WITH ADVANCED SOLID TUMORS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv149-iv150. PMID 28170899 DOI: 10.1093/Annonc/Mdu331.10  0.306
2014 Munoz J, Wheler J, Kurzrock R. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. Cancer Metastasis Reviews. PMID 25543191 DOI: 10.1007/S10555-014-9543-Z  0.314
2014 Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 5: 11154-67. PMID 25525888 DOI: 10.18632/Oncotarget.2568  0.33
2014 Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 5: 11168-79. PMID 25426553 DOI: 10.18632/Oncotarget.2584  0.379
2014 Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, ... ... Kurzrock R, et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 5: 10280-92. PMID 25373733 DOI: 10.18632/Oncotarget.2163  0.679
2014 Randall JM, Millard F, Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Reviews. 33: 1109-24. PMID 25365943 DOI: 10.1007/S10555-014-9533-1  0.333
2014 Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, et al. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1629-49. PMID 25361808 DOI: 10.6004/Jnccn.2014.0161  0.354
2014 Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Research. 74: 7181-4. PMID 25326492 DOI: 10.1158/0008-5472.Can-14-2329  0.384
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, ... ... Kurzrock R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293  0.35
2014 Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, et al. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5956-63. PMID 25316815 DOI: 10.1158/1078-0432.Ccr-14-1582  0.322
2014 Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, et al. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 5: 8937-46. PMID 25313136 DOI: 10.18632/ONCOTARGET.2339  0.365
2014 Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, et al. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Molecular Cancer Therapeutics. 13: 3175-84. PMID 25253784 DOI: 10.1158/1535-7163.Mct-14-0358  0.388
2014 Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. Plos One. 9: e93676. PMID 25119929 DOI: 10.1371/Journal.Pone.0093676  0.314
2014 Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clinical Epigenetics. 6: 13. PMID 25024751 DOI: 10.1186/1868-7083-6-13  0.311
2014 Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 5: 3607-10. PMID 25003820 DOI: 10.18632/Oncotarget.1964  0.303
2014 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 5: 3871-9. PMID 25003695 DOI: 10.18632/Oncotarget.2004  0.326
2014 Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4827-36. PMID 24987059 DOI: 10.1158/1078-0432.Ccr-14-0603  0.356
2014 Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4449-58. PMID 24958809 DOI: 10.1158/1078-0432.Ccr-14-0887  0.308
2014 Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 5: 3012-22. PMID 24931142 DOI: 10.18632/Oncotarget.1687  0.356
2014 Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Investigational New Drugs. 32: 1204-12. PMID 24919855 DOI: 10.1007/S10637-014-0127-0  0.385
2014 Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Investigational New Drugs. 32: 1181-7. PMID 24879333 DOI: 10.1007/S10637-014-0121-6  0.344
2014 Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treatment Reviews. 40: 883-91. PMID 24867380 DOI: 10.1016/J.Ctrv.2014.05.003  0.324
2014 Bendell JC, Hong DS, Burris HA, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74: 125-30. PMID 24819685 DOI: 10.1007/S00280-014-2480-2  0.327
2014 Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, ... ... Kurzrock R, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 5: 2349-54. PMID 24811890 DOI: 10.18632/Oncotarget.1946  0.383
2014 Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. The Oncologist. 19: 631-6. PMID 24797821 DOI: 10.1634/Theoncologist.2013-0405  0.334
2014 Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investigational New Drugs. 32: 717-22. PMID 24764123 DOI: 10.1007/S10637-014-0104-7  0.315
2014 Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, ... ... Kurzrock R, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 120: 2164-73. PMID 24752867 DOI: 10.1002/Cncr.28701  0.371
2014 Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. The Lancet. Oncology. 15: 656-66. PMID 24746841 DOI: 10.1016/S1470-2045(14)70155-X  0.307
2014 Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 5: 1846-55. PMID 24742900 DOI: 10.18632/Oncotarget.1834  0.343
2014 Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, ... Kurzrock R, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5: 1837-45. PMID 24742823 DOI: 10.18632/Oncotarget.1828  0.397
2014 Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treatment Reviews. 40: 770-80. PMID 24656976 DOI: 10.1016/J.Ctrv.2014.02.008  0.375
2014 Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 194-203. PMID 24586081 DOI: 10.6004/Jnccn.2014.0020  0.395
2014 Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Reports. 6: 377-87. PMID 24440717 DOI: 10.1016/J.Celrep.2013.12.035  0.418
2014 Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemotherapy and Pharmacology. 73: 495-501. PMID 24435060 DOI: 10.1007/S00280-014-2384-1  0.318
2014 Kurzrock R, Kantarjian H, Stewart DJ. A cancer trial scandal and its regulatory backlash. Nature Biotechnology. 32: 27-31. PMID 24406925 DOI: 10.1038/Nbt.2792  0.317
2014 Schroeder RD, Angelo LS, Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 5: 67-77. PMID 24393766 DOI: 10.18632/Oncotarget.1557  0.724
2014 Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Investigational New Drugs. 32: 465-72. PMID 24306314 DOI: 10.1007/S10637-013-0051-8  0.365
2014 Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Investigational New Drugs. 32: 436-44. PMID 24258465 DOI: 10.1007/S10637-013-0046-5  0.303
2014 Falchook GS, Lippman SM, Bastida CC, Kurzrock R. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head & Neck. 36: E25-7. PMID 23852769 DOI: 10.1002/Hed.23429  0.36
2014 Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Investigational New Drugs. 32: 279-86. PMID 23756764 DOI: 10.1007/S10637-013-9966-3  0.353
2014 Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 4: 705-14. PMID 23670029 DOI: 10.18632/Oncotarget.974  0.351
2014 Fontes Jardim DL, Gagliato DDM, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir NM, Corn PG, Tang C, Hess KR, Roy-Chowdhuri S, Kurzrock R, et al. c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. Journal of Clinical Oncology. 32: 407-407. DOI: 10.1200/Jco.2014.32.4_Suppl.407  0.357
2014 Arguello D, Millis SZ, Gatalica Z, Yan M, Kurzrock R. HER2 distribution in diverse tumors: Analysis of 11,493 nonbreast, nongastric cancers. Journal of Clinical Oncology. 32: e22200-e22200. DOI: 10.1200/Jco.2014.32.15_Suppl.E22200  0.36
2014 Legendre BL, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner R, Subbiah V, Tsimberidou AM, Luthra R, Meric-Bernstam F, Bedikian AY, ... ... Kurzrock R, et al. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. Journal of Clinical Oncology. 32: e22147-e22147. DOI: 10.1200/Jco.2014.32.15_Suppl.E22147  0.358
2014 Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, ... ... Kurzrock R, et al. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). Journal of Clinical Oncology. 32: e22139-e22139. DOI: 10.1200/Jco.2014.32.15_Suppl.E22139  0.334
2014 Huang M, Parkhurst KL, Jiang Y, Moulder SL, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Fu S, Tsimberidou AM, Zinner R, Janku F, Kurzrock R, Falchook GS. HER2 extracellular domain (ECD) and HER2 single nucleotide polymorphisms (SNPs) in patients treated with combination trastuzumab, lapatinib, and bevacizumab. Journal of Clinical Oncology. 32: e22082-e22082. DOI: 10.1200/Jco.2014.32.15_Suppl.E22082  0.306
2014 Subbiah V, Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong DS, Falchook GS, Anderson PM, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha-Paul SA, Janku F, ... ... Kurzrock R, et al. Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. Journal of Clinical Oncology. 32: e21024-e21024. DOI: 10.1200/Jco.2014.32.15_Suppl.E21024  0.38
2014 Tsimberidou AM, Ye Y, Wheler JJ, Falchook GS, Hong DS, Naing A, Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, et al. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. Journal of Clinical Oncology. 32: e13521-e13521. DOI: 10.1200/Jco.2014.32.15_Suppl.E13521  0.4
2014 Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Velez Bravo VM, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, ... ... Kurzrock R, et al. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Journal of Clinical Oncology. 32: 8508-8508. DOI: 10.1200/Jco.2014.32.15_Suppl.8508  0.363
2014 Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, et al. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. Journal of Clinical Oncology. 32: 3607-3607. DOI: 10.1200/Jco.2014.32.15_Suppl.3607  0.311
2014 Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan D, Kurzrock R, Sun P, Cunningham EA, Orford KW, Motwani M, Bai Y, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. Journal of Clinical Oncology. 32: 3517-3517. DOI: 10.1200/Jco.2014.32.15_Suppl.3517  0.362
2014 Wheler JJ, Janku F, Atkins JT, Moulder SL, Zinner R, Lee JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, Karp DD, Naing A, Fu S, Hong DS, Subbiah V, Stephens PJ, ... ... Kurzrock R, et al. PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. Journal of Clinical Oncology. 32: 2606-2606. DOI: 10.1200/Jco.2014.32.15_Suppl.2606  0.336
2014 Hou M, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. Journal of Clinical Oncology. 32: 2576-2576. DOI: 10.1200/Jco.2014.32.15_Suppl.2576  0.354
2014 Falchook GS, Goldman JW, Desai J, Leitch I, Hong DS, Subbiah V, Kurzrock R, Rosen LS. A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 2524-2524. DOI: 10.1200/Jco.2014.32.15_Suppl.2524  0.339
2014 Lin NU, Gabrail NY, Sarantopoulos J, Schwartzberg LS, Kesari S, Bates SE, Anders CK, Elias AD, Castaigne J, Iordanova V, Lawrence B, Kurzrock R. Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. Journal of Clinical Oncology. 32: 2523-2523. DOI: 10.1200/Jco.2014.32.15_Suppl.2523  0.337
2014 Kurzrock R, Galanis E, Johnson DR, Kansra V, Wilcoxen K, Mcclure T, Martell RE, Agarwal S. A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer. Journal of Clinical Oncology. 32: 2092-2092. DOI: 10.1200/Jco.2014.32.15_Suppl.2092  0.336
2014 Fontes Jardim DL, Schwaederle MC, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval. Journal of Clinical Oncology. 32: 11047-11047. DOI: 10.1200/Jco.2014.32.15_Suppl.11047  0.33
2014 Abdel-Wahab OI, Diamond EL, Patel M, Holley VR, Cabrilo G, Rampal R, Hassaine L, Kosco K, Baselga J, Kurzrock R, Poole J, Vibat CRT, Erlander M, Janku F, Hyman DM. Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients. Journal of Clinical Oncology. 32: 11012-11012. DOI: 10.1200/Jco.2014.32.15_Suppl.11012  0.323
2014 Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S, Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, ... ... Kurzrock R, et al. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. Journal of Clinical Oncology. 32: 10531-10531. DOI: 10.1200/Jco.2014.32.15_Suppl.10531  0.344
2014 Fajgenbaum DC, Liu A, Ruth J, Nabel C, Finkelman B, Kurzrock R, van Rhee F, Rubenstein A. HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review Blood. 124: 4861-4861. DOI: 10.1182/Blood.V124.21.4861.4861  0.32
2014 Madlensky L, Schwab R, Arthur E, Coutinho A, Parker B, Kurzrock R. Abstract 15: Identifying patients with inherited cancer susceptibility through tumor profiling Cancer Research. 74: 15-15. DOI: 10.1158/1538-7445.Cansusc14-15  0.403
2014 Hong D, Kim Y, Younes A, Nemunaitis J, Fowler N, Hsu J, Zhou T, Fayad L, Zhang N, Piha-Paul S, Woessner R, Nadella MV, Lawson D, Reimer C, Jo M, ... ... Kurzrock R, et al. Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3 Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-227  0.396
2014 Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda JG, Zheng H, Klevesath MB, Köhler K, Bladt F, Johne A, Kurzrock R. Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct236  0.325
2014 Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook G, Piha-Paul S, Zinner R, Rodriguez-Canales J, He G, Siddik ZH, Jelinek J, Chung W, Ye Y, Said R, ... ... Kurzrock R, et al. Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct201  0.348
2014 Janku F, Legendre B, Richardson K, Falchook GS, Naing A, Holley VR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Zinner RG, Subbiah V, Tsimberidou AM, Karp DD, Stepanek VM, ... ... Kurzrock R, et al. Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers Cancer Research. 74: 5607-5607. DOI: 10.1158/1538-7445.Am2014-5607  0.398
2014 Huang HJ, Claes B, Falchook GS, Holley VR, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner RG, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Stepanek VM, Cabrilo G, ... ... Kurzrock R, et al. Abstract 5584: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (IdyllaTM) Cancer Research. 74: 5584-5584. DOI: 10.1158/1538-7445.Am2014-5584  0.391
2014 Liu X, Hou M, Wheler J, Naing A, Hong D, Tsimberidou A, Piha-Paul S, Falchook G, Zinner R, Janku F, Lois R, Schmeler K, Lu K, Kurzrock R, Fu S. Abstract 2838: Differential effects of PIK3CA mutations and PTEN loss in patients with advanced endometrial cancers on matched therapy Cancer Research. 74: 2838-2838. DOI: 10.1158/1538-7445.Am2014-2838  0.417
2014 Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz CM, Issa J, Kurzrock R, Wistuba II. Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples Cancer Research. 74: 2303-2303. DOI: 10.1158/1538-7445.Am2014-2303  0.36
2014 Janku F, Garrido-Laguna I, Velez-Bravo V, Falchook G, Subbiah V, Hong D, Oki Y, Westin J, Nunez C, Fayad L, Kwak L, Neelapu S, Shpall E, Wheler J, Lang W, ... ... Kurzrock R, et al. Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients Klinische PäDiatrie. 226. DOI: 10.1055/S-0034-1371153  0.318
2014 Janku F, Huang H, Claes B, Falchook G, Naing A, Piha-Paul S, Tsimberidou A, Zinner R, Karp D, Fu S, Subbiah V, Hong D, Wheler J, Luthra R, Patel S, ... ... Kurzrock R, et al. 169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) European Journal of Cancer. 50: 56-57. DOI: 10.1016/S0959-8049(14)70295-3  0.411
2013 Rosen PJ, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg RD, Shubhakar P, Zoog S, Beaupre DM, Lee P. First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 41. PMID 28137005 DOI: 10.1200/Jco.2013.31.6_Suppl.41  0.335
2013 Kurzrock R, Gopalakrishnan V, Zwelling LA. A rapid method to estimate the value of genetic analysis of excised cancers: A comparison in the phase I setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 264. PMID 28136435 DOI: 10.1200/Jco.2013.31.31_Suppl.264  0.34
2013 Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepato-Gastroenterology. 60: 1611-23. PMID 24634931 DOI: 10.5754/Hge12257  0.383
2013 Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 85: 350-5. PMID 24335388 DOI: 10.1159/000355691  0.306
2013 Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 3004-11. PMID 24158411 DOI: 10.1093/Annonc/Mdt395  0.367
2013 Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. The Oncologist. 18: 1315-20. PMID 24153239 DOI: 10.1634/Theoncologist.2013-0202  0.346
2013 Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, ... Kurzrock R, et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Molecular Cancer Therapeutics. 12: 2857-63. PMID 24092809 DOI: 10.1158/1535-7163.Mct-13-0319-T  0.383
2013 Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, ... Kurzrock R, et al. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5474-84. PMID 24089446 DOI: 10.1158/1078-0432.Ccr-12-3110  0.343
2013 Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemotherapy and Pharmacology. 72: 1089-96. PMID 24057042 DOI: 10.1007/S00280-013-2297-4  0.364
2013 Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Molecular Cancer Therapeutics. 12: 2167-75. PMID 23963360 DOI: 10.1158/1535-7163.Mct-12-1208  0.385
2013 Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). Plos One. 8: e68985. PMID 23922674 DOI: 10.1371/Journal.Pone.0068985  0.311
2013 Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Investigational New Drugs. 31: 1192-200. PMID 23907406 DOI: 10.1007/S10637-013-0003-3  0.346
2013 Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4824-31. PMID 23873691 DOI: 10.1158/1078-0432.Ccr-13-0477  0.361
2013 Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 4: 772-84. PMID 23800712 DOI: 10.18632/Oncotarget.1028  0.382
2013 Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 4: 884-9. PMID 23800680 DOI: 10.18632/Oncotarget.1021  0.723
2013 Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 4: 890-8. PMID 23765114 DOI: 10.18632/Oncotarget.1015  0.432
2013 Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e351-2. PMID 23733763 DOI: 10.1200/Jco.2012.45.7739  0.319
2013 Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2256-61. PMID 23676418 DOI: 10.1093/Annonc/Mdt177  0.365
2013 Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3659-70. PMID 23659971 DOI: 10.1158/1078-0432.Ccr-12-3349  0.352
2013 Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. Journal of the National Cancer Institute. 105: 833. PMID 23628598 DOI: 10.1093/Jnci/Djt100  0.396
2013 Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. Bmc Cancer. 13: 193. PMID 23587187 DOI: 10.1186/1471-2407-13-193  0.358
2013 Henary H, Hong DS, Falchook GS, Tsimberidou AM, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul SA, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes Annals of Oncology. 24: 2158-2165. PMID 23576709 DOI: 10.1093/Annonc/Mdt115  0.323
2013 Janku F, Huang HJ, Angelo LS, Kurzrock R. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget. 4: 463-73. PMID 23531874 DOI: 10.18632/Oncotarget.886  0.688
2013 Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 4: 310-5. PMID 23470635 DOI: 10.18632/Oncotarget.864  0.351
2013 Kurzrock R, Stewart DJ. Compliance in early-phase cancer clinical trials research. The Oncologist. 18: 308-13. PMID 23457001 DOI: 10.1634/Theoncologist.2012-0260  0.34
2013 Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. Journal of Cancer Research and Clinical Oncology. 139: 963-70. PMID 23455881 DOI: 10.1007/S00432-013-1404-6  0.391
2013 Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer Oncotarget. 4: 118-127. PMID 23435217 DOI: 10.18632/Oncotarget.763  0.336
2013 Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies European Journal of Cancer. 49: 1521-1529. PMID 23433846 DOI: 10.1016/J.Ejca.2013.01.013  0.344
2013 Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British Journal of Cancer. 108: 826-30. PMID 23412108 DOI: 10.1038/Bjc.2013.46  0.336
2013 Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation Targeted Oncology. 8: 183-188. PMID 23400451 DOI: 10.1007/S11523-013-0266-9  0.337
2013 Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 4: 156-65. PMID 23391555 DOI: 10.18632/Oncotarget.832  0.41
2013 Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Investigational New Drugs. 31: 967-73. PMID 23361621 DOI: 10.1007/S10637-013-9929-8  0.312
2013 Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: e19-20. PMID 23328556 DOI: 10.1097/Jto.0B013E31827Ce38E  0.353
2013 Janku F, Munoz J, Subbiah V, Kurzrock R. A tale of two histiocytic disorders. The Oncologist. 18: 2-4. PMID 23299771 DOI: 10.1634/Theoncologist.2012-0440  0.394
2013 Angelo LS, Maxwell DS, Wu JY, Sun D, Hawke DH, McCutcheon IE, Slopis JM, Peng Z, Bornmann WG, Kurzrock R. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorganic & Medicinal Chemistry. 21: 932-9. PMID 23294827 DOI: 10.1016/J.Bmc.2012.12.008  0.693
2013 Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions Cancer Treatment Reviews. 39: 375-387. PMID 23199899 DOI: 10.1016/J.Ctrv.2012.10.001  0.319
2013 Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Investigational New Drugs. 31: 918-26. PMID 23179336 DOI: 10.1007/S10637-012-9898-3  0.377
2013 Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials Cancer Research. 73: 276-284. PMID 23066039 DOI: 10.1158/0008-5472.Can-12-1726  0.371
2013 Subbiah IM, Janku F, Tsimberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials. Journal of Clinical Oncology. 31: 281-281. DOI: 10.1200/Jco.2013.31.4_Suppl.281  0.362
2013 Subbiah IM, Subbiah V, Naing A, Fu S, Kaseb AO, Falchook GS, Tan D, Herzog CE, Janku F, Kurzrock R. Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma. Journal of Clinical Oncology. 31: 232-232. DOI: 10.1200/Jco.2013.31.4_Suppl.232  0.372
2013 Falchook GS, Desai J, Leitch IM, Goldman JW, Wheler JJ, Fu S, Kurzrock R, Baldwin M, Rosen LS. Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2619  0.312
2013 Liu X, Hong DS, Fu S, Piha-Paul SA, McQuinn L, Falchook GS, Williams J, Karp DD, Subbiah V, Tsimberidou AM, Janku F, Zinner R, Wheler JJ, Wolff RA, Kurzrock R, et al. Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. Journal of Clinical Oncology. 31: e13575-e13575. DOI: 10.1200/Jco.2013.31.15_Suppl.E13575  0.38
2013 Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJE, Swart RE, Walker MS, Munster PN, Dees EC, Marshall J, Hamid O, Kurzrock R. Phase Ib study of safety, tolerability, and efficacy of R1507 a monoclonal antibody to IGF-1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies. Journal of Clinical Oncology. 31: e13574-e13574. DOI: 10.1200/Jco.2013.31.15_Suppl.E13574  0.349
2013 Hou M, Liu X, Wheler JJ, Naing A, Hong DS, Bodurka DC, Schmeler KM, Tsimberidou AM, Janku F, Zinner R, Piha-Paul SA, Lu KH, Wolff RA, Kurzrock R, Fu S. Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. Journal of Clinical Oncology. 31: e13534-e13534. DOI: 10.1200/Jco.2013.31.15_Suppl.E13534  0.326
2013 Subbiah IM, Wheler JJ, Hess KR, Hong DS, Fu S, Wolff RA, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. Journal of Clinical Oncology. 31: 9544-9544. DOI: 10.1200/Jco.2013.31.15_Suppl.9544  0.351
2013 Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, Kwoh TJ, MacLeod AR, Norris D, Baldwin R, ... ... Kurzrock R, et al. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. Journal of Clinical Oncology. 31: 8523-8523. DOI: 10.1200/Jco.2013.31.15_Suppl.8523  0.341
2013 Cohen EE, Hong DS, Pfister DG, Salgia R, Burtness B, Cohen RB, Ball DW, Mehra R, Mangeshkar M, Yaron Y, Bentzien F, Kurzrock R. Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. Journal of Clinical Oncology. 31: 6090-6090. DOI: 10.1200/Jco.2013.31.15_Suppl.6090  0.316
2013 Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan DP, Kurzrock R, Atreya CE, Luan J, Sun P, Schaeffer M, Motwani M, Bleam MR, et al. Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). Journal of Clinical Oncology. 31: 3507-3507. DOI: 10.1200/Jco.2013.31.15_Suppl.3507  0.332
2013 Westin SN, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V, Culotta KS, ... ... Kurzrock R, et al. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. Journal of Clinical Oncology. 31: 2611-2611. DOI: 10.1200/Jco.2013.31.15_Suppl.2611  0.342
2013 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Wolff RA, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. Journal of Clinical Oncology. 31: 2545-2545. DOI: 10.1200/Jco.2013.31.15_Suppl.2545  0.347
2013 Fontes Jardim DL, Hess KR, LoRusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety and final approved dose in later trials: Analysis of 33,845 patients. Journal of Clinical Oncology. 31: 2509-2509. DOI: 10.1200/Jco.2013.31.15_Suppl.2509  0.313
2013 Huang HJ, Devogelaere B, Falchook GS, Fu S, Angelo LS, Hong DS, Piha-Paul SA, Naing A, Holley VR, Tsimberidou AM, Stepanek VMT, Kim K, Subbiah V, Wheler JJ, Zinner R, ... ... Kurzrock R, et al. BRAF mutation testing with a novel, rapid, fully automated molecular diagnostics prototype platform. Journal of Clinical Oncology. 31: 11086-11086. DOI: 10.1200/Jco.2013.31.15_Suppl.11086  0.714
2013 Wheler JJ, Yelensky R, Moulder SL, Tsimberidou AM, Falchook GS, Janku F, Atkins JT, Zinner R, Karp DD, Hong DS, Stephens P, Wolff RA, Kurzrock R. Next-generation sequencing (NGS) in patients with advanced metastatic breast cancer: Identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center. Journal of Clinical Oncology. 31: 1051-1051. DOI: 10.1200/Jco.2013.31.15_Suppl.1051  0.401
2013 Van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease Blood. 122: 1806-1806. DOI: 10.1182/Blood.V122.21.1806.1806  0.335
2013 Bendell JC, Janku F, Infante J, Jones S, Burris H, Golden L, Hynes SM, Lin J, Bence AK, Tse S, Kurzrock R, Hong D. Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-200  0.341
2013 Subbiah IM, Janku F, Naing A, Fu S, Hong DS, Kaseb AO, Herzog C, Kurzrock R, Wolff RA, Subbiah V. Abstract 48: Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. Cancer Research. 73: 48-48. DOI: 10.1158/1538-7445.Am2013-48  0.424
2013 Janku F, Angelo LS, Devogelaere B, Fachook GS, Fu S, Huang HJ, Tsimberidou AM, Hong DS, Stepanek VM, Holley VR, Routbort MJ, Sablon E, Maertens G, Kurzrock R. Abstract 4126: BRAF mutation testing with a novel, rapid, fully-automated molecular diagnostics prototype platform. Cancer Research. 73: 4126-4126. DOI: 10.1158/1538-7445.Am2013-4126  0.724
2013 Kadowaki T, Funahashi Y, Matsui J, Pavan K, Sachdev P, O'Brien J, Xing H, McDonagh PD, Khalil I, Kurzrock R, Hong DS, Nemunaitis J. Abstract 4025: Data-driven computational modeling to identify biomarkers of response to lenvatinib (E7080) in melanoma. Cancer Research. 73: 4025-4025. DOI: 10.1158/1538-7445.Am2013-4025  0.363
2013 Chae YK, Kim K, Hong DS, Falchook GS, Piha-Paul SA, Wheler JJ, Naing A, Fu S, Tsimberidou AM, Zinner RG, Subbiah V, Stepanek VM, Wolff RA, Kurzrock R, Janku F. Abstract 164: PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials . Cancer Research. 73: 164-164. DOI: 10.1158/1538-7445.Am2013-164  0.351
2013 Zinner R, Atkins JT, Janku F, Moulder S, Stephens P, Yelensky R, Wolff R, Kurzrock R, Wheler JJ. Abstract 1209: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition. Cancer Research. 73: 1209-1209. DOI: 10.1158/1538-7445.Am2013-1209  0.395
2013 Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff R, Tsimberidou AM. Abstract 1178: Phase I clinical trial of Lenalidomide in combination with Sorafenib in patients with advanced cancer. Cancer Research. 73: 1178-1178. DOI: 10.1158/1538-7445.Am2013-1178  0.364
2013 Agarwal R, Naing A, Falchook G, Wheler J, Fu S, Kurzrock R. Abstract 1177: Retreatment after secondary resistance: A pilot study. Cancer Research. 73: 1177-1177. DOI: 10.1158/1538-7445.Am2013-1177  0.375
2013 Bilen MA, Fu S, Hong DS, Wheler JJ, Abdelrahim M, Falchook GS, Tsimberidou AM, Janku F, Piha-Paul S, Zinner R, Kurzrock R, Naing A. Abstract C69: Phase I trial of lenalidomide and valproic acid in patients with advanced cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C69  0.376
2013 Janku F, Legendre B, Richardson K, Falchook GS, Naing A, Holley VR, Hong DS, Zinner RG, Fu S, Tsimberidou AM, Subbiah V, Karp DD, Piha-Paul SA, Wheler JJ, Stepanek VM, ... ... Kurzrock R, et al. Abstract C203: BRAF and KRAS mutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C203  0.404
2013 Huang HJ, Claes B, Falchook GS, Devogelaere B, Naing A, Fu S, Piha-Paul S, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Kim KB, Angelo LS, Subbiah V, Wheler JJ, ... ... Kurzrock R, et al. Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C198  0.375
2013 Janku F, Kurzrock R, Helgason T, Valero V, Esteva F, Wheler JJ, Karp DD, Meric-Bernstam F, Moulder SL. Abstract C120: Genomic landscape in advanced metaplastic breast cancer and outcomes with mTOR targeted therapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C120  0.412
2013 Abdelrahim M, Naing A, Dalal S, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Abstract B82: Olanzapine for cachexia in patients with advanced cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B82  0.357
2013 Azad N, Ball D, Sherman S, Rudek M, Falchook G, Nelkin B, Janku F, Papadopoulos N, O'Conner A, Ahmed S, Wilky B, Markus S, Gong J, Cosgrove D, Zahurak M, ... ... Kurzrock R, et al. Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B279  0.392
2013 Janku F, Angenendt P, Naing A, Falchook GS, Tsimberidou AM, Holley VR, Fu S, Hong DS, Wheler JJ, Piha-Paul SA, Zinner RG, Karp DD, Subbiah V, Kim KB, Meric-Bernstam F, ... ... Kurzrock R, et al. Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B26  0.391
2013 Hou M, Liu X, Piha-Paul SA, Janku F, Wheler J, Naing A, Bodurka D, Schmeler K, Lu K, Zinner R, Hong D, Meric-Bernstam F, Kurzrock R, Fu S. Abstract B191: Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B191  0.41
2013 Wheler JJ, Parker BA, Lee J, Yelensky R, Moulder S, Tsimberidou AM, Janku F, Atkins JT, Zinner R, Schwab RQ, Schwaederle M, Subbiah V, Fu S, Stephens PJ, Kurzrock R. Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A212  0.417
2013 Huang HJ, Claes B, Falchook GS, Tsimberidou AM, Holley VR, Subbiah V, Zinner RG, Naing A, Karp DD, Piha-Paul SA, Wheler JJ, Fu S, Hong DS, Stepanek VM, Luthra R, ... ... Kurzrock R, et al. Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A202  0.402
2013 Parker B, Schwab R, Helsten T, Sarah B, Ojeda-Fournier H, Datnow B, Schwaederle M, Coutinho A, Kurzrock R. Abstract P4-04-15: UC San Diego molecular tumor board: Experience in breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-04-15  0.382
2013 Ganesan P, Moulder S, Janku F, Naing A, Fu S, Tsimberidou A, Hong D, Stephens P, Yelensky R, Meric F, Kurzrock R, Wheler J. Abstract P1-08-18: PIK/AKT/MTOR pathway activation in triple negative breast cancer and outcomes with matched therapy in phase I clinical trials: Response in both patients with and without direct molecular alterations Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-08-18  0.379
2013 Westin S, Sun C, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R, Kurzrock R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease Gynecologic Oncology. 130: e162. DOI: 10.1016/J.Ygyno.2013.04.453  0.307
2012 Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 23: 1963-1967. PMID 32018447 DOI: 10.1093/Annonc/Mds027  0.373
2012 Janku F, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Fu S, Piha-Paul SA, Luthra R, Hong DS, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 459. PMID 27983190 DOI: 10.1200/Jco.2012.30.4_Suppl.459  0.402
2012 Subbiah IM, Subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-Paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 364. PMID 27982931 DOI: 10.1200/Jco.2012.30.4_Suppl.364  0.367
2012 Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Jack Lee J, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: Characteristics and outcomes Oncotarget. 3: 1566-1575. PMID 23248156 DOI: 10.18632/Oncotarget.716  0.358
2012 Westin JR, Kurzrock R. It's about time: Lessons for solid tumors from chronic myelogenous leukemia therapy Molecular Cancer Therapeutics. 11: 2549-2555. PMID 23204432 DOI: 10.1158/1535-7163.Mct-12-0473  0.382
2012 Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology. 71: 389-97. PMID 23143207 DOI: 10.1007/S00280-012-2014-8  0.334
2012 Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 24: 838-42. PMID 23139256 DOI: 10.1093/Annonc/Mds524  0.362
2012 Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6356-63. PMID 23014530 DOI: 10.1158/1078-0432.Ccr-12-0178  0.372
2012 Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6373-83. PMID 22966018 DOI: 10.1158/1078-0432.Ccr-12-1627  0.398
2012 Munoz J, Kurzrock R. Targeted therapy in rare cancers--adopting the orphans. Nature Reviews. Clinical Oncology. 9: 631-42. PMID 22965154 DOI: 10.1038/Nrclinonc.2012.160  0.312
2012 Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5796-805. PMID 22927482 DOI: 10.1158/1078-0432.Ccr-12-1158  0.305
2012 Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Molecular Cancer Therapeutics. 11: 2541-6. PMID 22914439 DOI: 10.1158/1535-7163.Mct-12-0358  0.348
2012 Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Molecular Cancer Therapeutics. 11: 2483-94. PMID 22914438 DOI: 10.1158/1535-7163.Mct-12-0580  0.322
2012 Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, ... ... Kurzrock R, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The Lancet. Oncology. 13: 782-9. PMID 22805292 DOI: 10.1016/S1470-2045(12)70269-3  0.351
2012 Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, ... Kurzrock R, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet. Oncology. 13: 773-81. PMID 22805291 DOI: 10.1016/S1470-2045(12)70270-X  0.317
2012 Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2891-6. PMID 22778314 DOI: 10.1200/Jco.2011.38.0758  0.329
2012 Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4173-82. PMID 22693357 DOI: 10.1158/1078-0432.Ccr-12-0714  0.399
2012 Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2684-90. PMID 22689801 DOI: 10.1200/Jco.2011.36.4752  0.32
2012 Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: Outcome after treatment with early-phase trials with targeted pathway inhibitors Plos One. 7. PMID 22675430 DOI: 10.1371/Journal.Pone.0038033  0.406
2012 Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 118: 6144-51. PMID 22674635 DOI: 10.1002/Cncr.27647  0.361
2012 Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3396-406. PMID 22634319 DOI: 10.1158/1078-0432.Ccr-11-2703  0.347
2012 Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 379: 1893-901. PMID 22608338 DOI: 10.1016/S0140-6736(12)60398-5  0.335
2012 Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepato-Gastroenterology. 59: 960-4. PMID 22580643 DOI: 10.5754/Hge12189  0.334
2012 Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clinical Colorectal Cancer. 11: 297-303. PMID 22537607 DOI: 10.1016/J.Clcc.2012.02.001  0.364
2012 Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, ... ... Kurzrock R, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2348-53. PMID 22529266 DOI: 10.1200/Jco.2011.36.8282  0.341
2012 Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Molecular Cancer Therapeutics. 11: 1221-5. PMID 22491798 DOI: 10.1158/1535-7163.Mct-11-0864  0.375
2012 Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, ... ... Kurzrock R, et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology. 126: 47-53. PMID 22487539 DOI: 10.1016/J.Ygyno.2012.04.006  0.334
2012 Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2922-9. PMID 22452943 DOI: 10.1158/1078-0432.Ccr-11-2217  0.361
2012 Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2326-35. PMID 22355009 DOI: 10.1158/1078-0432.Ccr-11-2515  0.361
2012 Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations Journal of Clinical Oncology. 30: 777-782. PMID 22271473 DOI: 10.1200/Jco.2011.36.1196  0.393
2012 Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. Plos One. 7: e29330. PMID 22235285 DOI: 10.1371/Journal.Pone.0029330  0.327
2012 Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutrition and Cancer. 64: 206-17. PMID 22229660 DOI: 10.1080/01635581.2012.638433  0.351
2012 Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase i trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies Cancer Chemotherapy and Pharmacology. 69: 1117-1126. PMID 22205203 DOI: 10.1007/s00280-011-1808-4  0.331
2012 Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: e64-8. PMID 22203760 DOI: 10.1200/Jco.2011.38.2614  0.389
2012 Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 11: 308-16. PMID 22203732 DOI: 10.1158/1535-7163.Mct-11-0566  0.37
2012 Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. International Journal of Hematology. 95: 1-2. PMID 22170230 DOI: 10.1007/S12185-011-0984-7  0.355
2012 Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 118: 1422-8. PMID 21823111 DOI: 10.1002/Cncr.26413  0.37
2012 Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, LoRusso PM. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Investigational New Drugs. 30: 327-34. PMID 20842406 DOI: 10.1007/S10637-010-9536-X  0.342
2012 Ahmed SR, Azad NS, Ball DW, Rudek MA, Nelkin B, Cosgrove D, Gong J, Finkelstein D, Zahurak M, Janku F, Downs M, O'Connor A, Markus S, Carducci MA, Sherman SI, ... Kurzrock R, et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. Journal of Clinical Oncology. 30: TPS3117-TPS3117. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps3117  0.398
2012 Kurzrock R, Blay J, Bui Nguyen B, Wagner AJ, Maki RG, Schwartz GK, Patnaik A, Gore L, Wu L, Vassilev LT, Ding M, Geho D, Zhi J, Middleton S, Nichols GL. A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. Journal of Clinical Oncology. 30: e13600-e13600. DOI: 10.1200/Jco.2012.30.15_Suppl.E13600  0.318
2012 Bilen MA, Naing A, Hong DS, Falchook GS, Fu S, Wen S, Wheler JJ, Durand J, Ewer M, Kurzrock R. Association between elevated blood pressure and clinical response in patients treated with anti-vascular endothelial growth factor (anti-VEGF) therapy in phase I clinical trials. Journal of Clinical Oncology. 30: e13506-e13506. DOI: 10.1200/Jco.2012.30.15_Suppl.E13506  0.332
2012 Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13020  0.35
2012 Henary HA, Hong DS, Falchook GS, Tsimberidou AM, George G, Wheler JJ, Fu S, Naing A, Piha-Paul SA, Janku F, Kim KB, Hwu P, Kurzrock R. Targeted agents matched with tumor molecular aberrations: Review of 160 patients with advanced melanoma treated in a phase I clinic. Journal of Clinical Oncology. 30: 8551-8551. DOI: 10.1200/Jco.2012.30.15_Suppl.8551  0.367
2012 Gordon MS, Kluger HM, Shapiro G, Kurzrock R, Edelman G, Samuel TA, Moussa AH, Ramies DA, Laird AD, Schimmoller F, Shen X, Daud A. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 30: 8531-8531. DOI: 10.1200/Jco.2012.30.15_Suppl.8531  0.344
2012 Winer EP, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak CA, Burris HA, Ramies DA, Rafferty T, Shen X. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 30: 535-535. DOI: 10.1200/Jco.2012.30.15_Suppl.535  0.349
2012 Naing A, LoRusso P, Fu S, Hong DS, Chen H, Doyle LA, Phan A, Habra MA, Kurzrock R. Activity of insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic refractory adrenocortical carcinoma. Journal of Clinical Oncology. 30: 4639-4639. DOI: 10.1200/Jco.2012.30.15_Suppl.4639  0.335
2012 Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel K, Kopetz S, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). Journal of Clinical Oncology. 30: 3528-3528. DOI: 10.1200/Jco.2012.30.15_Suppl.3528  0.387
2012 Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing A, Wheler JJ, Piha-Paul SA, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors. Journal of Clinical Oncology. 30: 3107-3107. DOI: 10.1200/Jco.2012.30.15_Suppl.3107  0.372
2012 Madhusudanannair V, Janku F, Falchook GS, Hong DS, Wheler JJ, Naing A, Fu S, Piha-Paul SA, El-Osta HE, Luthra R, Tsimberidou AM, Kurzrock R. NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. Journal of Clinical Oncology. 30: 3106-3106. DOI: 10.1200/Jco.2012.30.15_Suppl.3106  0.383
2012 Sarantopoulos J, Hoering A, Synold TW, Mahalingam D, Wang D, Lenz H, O'Rourke P, Sexton R, Van Veldhuizen PJ, Mita MM, Wong L, Mita AC, El-Khoueiry AB, Chung VM, Gandara DR, ... ... Kurzrock R, et al. Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study. Journal of Clinical Oncology. 30: 3078-3078. DOI: 10.1200/Jco.2012.30.15_Suppl.3078  0.312
2012 Bedard P, Tabernero J, Kurzrock R, Britten CD, Stathis A, Perez-Garcia JM, Zubel A, Le NT, Carter K, Bellew KM, Gallarati C, Niazi F, Demanse D, De Buck SS, Sessa C. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. Journal of Clinical Oncology. 30: 3003-3003. DOI: 10.1200/Jco.2012.30.15_Suppl.3003  0.329
2012 Angevin E, Elez E, Cohen SJ, Van Laethem J, Ottensmeier C, Joly F, Ray-Coquard I, Lopez-Martin JA, Dirix L, Machiels J, Clive S, Steven NM, Reddy M, Hall B, Puchalski T, ... ... Kurzrock R, et al. Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors. Journal of Clinical Oncology. 30: 2583-2583. DOI: 10.1200/Jco.2012.30.15_Suppl.2583  0.303
Show low-probability matches.